
Novartis’ Xolair scores European approval to treat chronic rhinosinusitis with nasal polyps
pharmafile | August 6, 2020 | News story | Sales and Marketing | Novartis, Xolair, rhinosinusitis
Novartis has snapped up approval from the European Commission for its anti-immunoglobulin E (IgE) antibody therapy Xolair (omalizumab) for the treatment of severe chronic rhinosinusitis with nasal polyps in adult patients, when used in combination with intranasal corticosteroids (INC).
The decision was reached after evaluating Phase 3 study data which showed that use of Xolair led to improvements in symptoms and quality of life, as well as reduced the size of nasal polyps, as measured by Nasal Polyp Score.
“People with chronic rhinosinusitis with nasal polyps can experience significant quality of life impairment as a result of their symptoms. The symptoms include long-term nasal congestion and blockage, sleep disruption and loss of smell and taste,” remarked Lars Ingemann, Academic Director at the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA). “The EUFOREA patient advisory board welcomes today’s approval, which will provide an additional treatment option to patients with severe chronic rhinosinusitis with nasal polyps.”
This latest authorisation adds to the existing approval of Xolair in the treatment of chronic spontaneous urticaria in more than 90 countries including the European Union, United States and Canada.
Matt Fellows
Related Content

Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …

Novartis candidate for Sjögren’s disease presents positive results
Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …

First malaria medicine for infants under 4.5kg receives approval
Coartem (artemether-lumefantrine) Baby, or Riamet, has been approved by Swissmedic as the first malaria medicine …






